SCHEMBL7620985

SCHEMBL7620985

COC(=O)c1cc(C(=O)NCc2ccc(OC)cc2)ccc1N

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.57
RAB9A P51151 4/20 0.57
NR1H4 Q96RI1 2/20 0.57
MEN1 O00255 1/20 0.57
EPHX2 P34913 1/20 0.57
KMT2A Q03164 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
ALDH1A1 P00352 3/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
HDAC1 Q13547 2/20 0.56
KDM4E B2RXH2 2/20 0.55
MAPT P10636 2/20 0.55
HPGD P15428 2/20 0.55
GAA P10253 1/20 0.55
ALOX15 P16050 1/20 0.55
TSHR P16473 1/20 0.55
HSD17B10 Q99714 1/20 0.55
PDE4A P27815 2/20 0.52
PDE4B Q07343 2/20 0.52
PDE4C Q08493 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6302398 0.93 NPC1 (0.55) NPC1RAB9ANR1H4MEN1EPHX2
SCHEMBL6296069 0.92 NPC1 (0.60) NPC1RAB9ANR1H4MEN1EPHX2
SCHEMBL6302829 0.90 NPC1 (0.60) NPC1RAB9ANR1H4MEN1EPHX2
SCHEMBL27214488 0.87 L3MBTL1 (0.56) RAB9AMEN1KMT2AL3MBTL1ALDH1A1
SCHEMBL6302831 0.85 NPC1 (0.56) NPC1RAB9ANR1H4MEN1EPHX2
SCHEMBL13175754 0.85 PDE4A (0.63) NPC1RAB9ANR1H4MEN1EPHX2
SCHEMBL30829109 0.83 NPC1 (0.62) NPC1RAB9ANR1H4MEN1EPHX2
SCHEMBL9416606 0.81 NPC1 (0.82) NPC1RAB9ANR1H4MEN1EPHX2
SCHEMBL11761142 0.81 NPC1 (0.82) NPC1RAB9ANR1H4MEN1EPHX2
SCHEMBL6239186 0.81 NPC1 (0.61) NPC1RAB9ANR1H4MEN1EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020193377-A1 Quinazolines as MMP-13 inhibitors ANDRIANJARA CHARLES (FR) 2002-12-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193377-A1 Quinazolines as MMP-13 inhibitors MMP13, MMP9, MMP3 NPC1 3752/4885RAB9A 1888/4885NR1H4 2332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.